Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis

Clinical and Experimental Rheumatology

Dennis Fryback¹  Dennis Revicki¹  Sumati Rao¹  Chris Thompson¹  Mary Cifaldi¹  Neesha Harnam¹  David Feeny¹  Miriam Kimel¹ 

关键词: Ankylosing spondylitis;    adalimumab;    health-related quality of life;    patient-reported outcomes;    physical functioning;    Short Form 36 Health Survey;    Health Utilities Index Mark 3;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: To compare the impact of ankylosing spondylitis (AS) on health-related quality of life (HRQL) and of adalimumab on initial and sustained improvement in HRQL for patients with active AS versus the general US population. METHODS: Data from the 5-year ATLAS trial were analysed. HRQL burden of AS and treatment impact on HRQL were assessed by comparing health status and utility scores from ATLAS (Short Form 36 Health Survey [SF-36] and Health Utilities Index Mark 3 [HUI3]) with population norms. RESULTS: Baseline scores for all measures were comparable between adalimumab and placebo. All scores for both groups were significantly worse than general population norms (all p

【 授权许可】

Unknown